stockrow
Friday 6 November 2026
Export ERAS’s income statement to Excel — free account
Erasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
14.34
1.07
+8.06%
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Operating cash flow
Erasca, Inc.'s operating cash flow for fiscal 2025 was −$95.5M, compared with −$109.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$98.0M. Over the past ten years it has ranged from −$109.4M (fiscal 2024) to −$10.4M (fiscal 2019); the current reading is higher than 57% of that period. Erasca, Inc. ranks 455th of 603 Biotechnology companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | −$95.5M | — |
| FY2024 | −$109.4M | — |
| FY2023 | −$101.2M | — |
| FY2022 | −$103.3M | — |
| FY2021 | −$79.6M | — |
| FY2020 | −$32.7M | — |
| FY2019 | −$10.4M | — |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | −$27.3M | — |
| Mar 2026 | −$27.4M | — |
| Dec 2025 | −$21.7M | — |
| Sep 2025 | −$21.7M | — |
| 22 more quarters | Free account |
Against its own ten years
Low −$109.4M
High −$10.4M
Ten-year median
−$95.5M
Current reading's percentile
57
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| TVTX Travere Therapeutics, Inc. compare | $176.6M |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −$89.4M |
| ERAS Erasca, Inc. | −$98.0M |
| MANE Veradermics Incorporated compare | −$122.9M |
| DFTX Definium Therapeutics, Inc. compare | −$168.0M |
| DNTH Dianthus Therapeutics, Inc. compare | −$175.2M |
| EWTX Edgewise Therapeutics, Inc. compare | −$201.9M |
| COGT Cogent Biosciences, Inc. compare | −$307.5M |
| CRSP CRISPR Therapeutics AG compare | −$374.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item